Boston (Press Release) - Acetylon Pharma­ceu­ticals, Inc., the leader in the devel­op­ment of selective histone deacetylase (HDAC) inhibitors for en­hanced thera­peutic out­comes, today announced that its selective HDAC inhibitor drug can­di­dates will be the subject of eleven presentations, in­­clud­ing three oral presentations and eight poster presentations of pre­clin­i­cal and clin­i­cal research in multiple myeloma, lym­phoma and sickle cell disease/β-thalassemia at the American Society of Hematology (ASH) Annual Meeting to be held De­cem­ber 7-10, 2013, in New Orleans, LA. The presentations will in­clude interim updates of two clin­i­cal trials of ACY-1215, a selective …

Melbourne, Australia (Press Release) - Patrys Limited (ASX:PAB), a clin­i­cal stage bio­technology com­pany has today announced that it is initiating an investigator-sponsored trial (IST) eval­u­ating the effectiveness of Patrys’ lead anti-cancer drug PAT-SM6 in com­bi­na­tion with car­filz­o­mib, in patients with re­lapsed and refractory multiple myeloma (MM). The trial will be headed by Professor Dr. Hermann Einsele, Director of the Department of Medicine II, University of Würzburg, Germany, and is being funded by Onyx Pharma­ceu­ti­cals, Inc., an Amgen sub­sid­i­ary.

Both clin­i­cal and pre­clin­i­cal studies of PAT-SM6 conducted to date have shown evi­dence of …

Thousand Oaks, CA and South San Francisco, CA (Press Release) - Amgen (NASDAQ:AMGN) and its sub­sid­i­ary Onyx Pharma­ceu­ticals, Inc. today announced that nearly 40 com­pany-sponsored and inves­ti­gator-sponsored inves­ti­ga­tional studies eval­u­ating car­filz­o­mib, a second-generation pro­te­a­some inhibitor, and oprozomib, an oral second-generation pro­te­a­some in­hib­i­tor in early devel­op­ment, will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition on December 7-10, 2013 at the Ernest N. Morial Convention Center in New Orleans, LA.

"We are encouraged by the breadth of data from our Proteasome Inhibitor franchise being presented this year …

Edmonton, Alberta (Press Release) - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharma­ceu­tical com­pany devel­op­ing and com­mer­cial­iz­ing prod­ucts for the treat­ment of cancer, announces the presentation of a late-breaking abstract at the 28^th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 9, 2013 in Maryland, U.S.  The work was jointly developed by Stanford Uni­ver­si­ty, AIT Strategies and Quest as con­tin­u­a­tion of an exclusive license agree­ment between Stanford Uni­ver­si­ty and Quest to develop and market anti-MUC1 IgE tech­nology for the treat­ment of cancer.

The title of the presentation is "MUC1 Specific IgE to Modify Myeloid Derived Cells …

Study is one of more than 160 abstracts eval­u­ating 10 Celgene com­­pounds across a range of blood cancers

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ:CELG) today announced that data from FIRST^® (Frontline Investigation of Lena­lido­mide + Dexa­meth­a­sone Versus Standard Thalido­mide), its phase III study (MM-020/IFM 07-01) of REV­LI­MID® (lena­lido­mide) in com­bi­na­tion with dex­a­meth­a­sone in patients newly diag­nosed with multiple myeloma (NDMM) in­eli­gible for stem cell trans­plant will be presented on Sunday, Dec. 8 during the plenary session of the 55^thAmerican Society of Hematology annual meeting in New Orleans, La.

Abstracts for the meeting were released today on the society’s …

South San Francisco, CA (Press Release) - Threshold Pharma­ceu­ticals, Inc. (NASDAQ:THLD) today an­nounced that clin­i­cal data on its inves­ti­ga­tional hypoxia-targeted drug, TH-302, will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), December 7 - 10, 2013, in New Orleans, LA. The presentations will report early data from two ongoing clin­i­cal trials, one eval­u­ating TH-302 as single-agent mono­therapy in patients with ad­vanced leukemias (Abstract #3920), and another eval­u­ating TH-302 with low-dose dexa­meth­a­sone in patients with re­lapsed / refractory multiple myeloma (Abstract #1948).

Abstract Details

Abstract #1948: Phase 1 Study of TH-302, an Investigational Hypoxia-Targeted …

Boulder, CO (Press Release) - Array BioPharma Inc. (NASDAQ: ARRY) today announced that five abstracts were accepted for presentation, in­­clud­ing two oral presentations, at the 2013 Annual Meeting of the Ameri­can Society of Hematology (ASH) on its two wholly-owned hematology drug can­di­dates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor.

Ron Squarer, Chief Executive Officer of Array, noted, "We look forward to the oppor­tu­ni­ty to present updates on ARRY-520 and ARRY-614 at the ASH meeting.  We believe that results from multiple clin­i­cal and pre­clin­i­cal studies of ARRY-520 will both dem­onstrate its …